Avalyn Pharma Inc. (AVLN) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 17, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Avalyn Pharma Inc. (AVLN), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Avalyn Pharma Inc., the average estimate for 2030 earnings per share is −$4.06; 4 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Avalyn Pharma Inc. (AVLN) forecast — frequently asked questions
What is the analyst price target for Avalyn Pharma Inc.?
Analysts covering Avalyn Pharma Inc. (AVLN) have a consensus price target of $60.00, 114.9% above the current price of $27.92. Published targets range from $51.00 to $80.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Avalyn Pharma Inc.'s earnings?
The average analyst estimate for Avalyn Pharma Inc. (AVLN) earnings per share in 2030 is -4.06, with individual estimates between -4.06 and -4.06.
How much revenue is Avalyn Pharma Inc. expected to make?
Analysts forecast Avalyn Pharma Inc. (AVLN) revenue of $0 in 2030, based on 1 published estimates.
How many analysts cover AVLN?
4 analysts contribute estimates for Avalyn Pharma Inc. (AVLN). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.